Start free

MapLight Therapeutics, Inc. (MPLT) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Oct 16, 2026.

Filings shown
39
Open-market buys
6
Open-market sells
106
Buys, 10b5-1 box not checked
6 of 6

Counts cover the 39 most recent Form 4 filings Tradune holds for MPLT (filed May 6 – Oct 16, 2026); the score below covers only the trailing 90 days (0 buys, 7 sells). SEC EDGAR Form 4 filings for MPLT last checked Nov 22, 2026, 09:00 UTC; the latest MPLT filing Tradune holds was filed Oct 16, 2026. This is not guaranteed to be the complete record — see MPLT's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 7 filings Tradune holds for MPLT filed Sep 18 – Oct 16, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

7 open-market sales by Rule 10b5-1 checkbox

On filings with the 10b5-1 box checked
1 sale· 16,509 sh
checkbox disclosed
On filings with the box not checked
6 sales· 131,994 sh
not proof that no plan exists
Not comparable
0 sales· 0 sh
filed before Apr 1, 2023, or no checkbox value in the filing data

Counts are Form 4 lines as filed. The checkbox is one per filing, so every sale on a filing with the box checked is counted there even if only some of its transactions were under a plan; it records what the filer disclosed, and the three categories are not a judgement about why a sale was made.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
Kristopher HansonGeneral Counsel 0 2 — 25,529 −$265,542
Christopher A. KroegerChief Executive Officer 0 1 — 73,691 −$595,423
Erin Pennock FoffChief Medical Officer 0 1 — 15,355 −$124,068
Anatol KreitzerChief Discovery Officer 0 1 — 12,248 −$96,024
James Woodruff LillieChief Scientific Officer 0 1 — 11,513 −$93,025
Jonathan GillisCAO and Interim CFO 0 1 — 10,167 −$82,149

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score

0/ 100

Net insider sales
0 distinct buyers0 buy · 7 sell tx

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at MPLT

Insiders reported 6 open-market purchases of MPLT between May 6, 2026 and Oct 16, 2026, across 2 distinct buyers. The most recent purchase was reported by Catalyst4, Inc. (10% owner) on Aug 14, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Anatol Kreitzer Chief Discovery Officer · filed Oct 16, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 12,248 $7.84 168,678 −6.8% Oct 15, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Erin Pennock Foff Chief Medical Officer · filed Oct 16, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 15,355 $8.08 296,906 −4.9% Oct 15, 2026
Kristopher Hanson General Counsel · filed Oct 16, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 9,020 $8.08 128,024 −6.6% Oct 15, 2026
James Woodruff Lillie Chief Scientific Officer · filed Oct 16, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 11,513 $8.08 198,597 −5.5% Oct 15, 2026
Jonathan Gillis CAO and Interim CFO · filed Oct 16, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 10,167 $8.08 142,315 −6.7% Oct 15, 2026
Christopher A. Kroeger Chief Executive Officer · filed Oct 16, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 73,691 $8.08 1,195,909 −5.8% Oct 15, 2026
Kristopher Hanson General Counsel · filed Sep 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 16,509 $11.67 137,044 −11% Sep 16, 2026
Anatol Kreitzer Chief Discovery Officer · filed Aug 19, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Employee Stock Option (right to buy) 24,455 — — — Aug 17, 2026
Grant / award 6,020 — 180,926 +3.4% Aug 17, 2026
Erin Pennock Foff Chief Medical Officer · filed Aug 19, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 13,360 — 312,261 +4.5% Aug 17, 2026
Grant / award Employee Stock Option (right to buy) 54,240 — — — Aug 17, 2026
Kristopher Hanson General Counsel · filed Aug 19, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 7,730 — 153,553 +5.3% Aug 17, 2026
Grant / award Employee Stock Option (right to buy) 31,395 — — — Aug 17, 2026
James Woodruff Lillie Chief Scientific Officer · filed Aug 19, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 7,730 — 210,110 +3.8% Aug 17, 2026
Grant / award Employee Stock Option (right to buy) 31,395 — — — Aug 17, 2026
Jonathan Gillis CAO and Interim CFO · filed Aug 19, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 6,020 — 150,260 +4.2% Aug 17, 2026
Grant / award 2,222 — 152,482 +1.5% Aug 17, 2026
Grant / award Employee Stock Option (right to buy) 24,455 — — — Aug 17, 2026
Grant / award Employee Stock Option (Right to Buy) 2,813 — — — Aug 17, 2026
Christopher A. Kroeger Chief Executive Officer · filed Aug 19, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 23,145 — 1,269,600 +1.9% Aug 17, 2026
Grant / award Employee Stock Option (right to buy) 93,955 — — — Aug 17, 2026
Catalyst4, Inc. 10% owner · filed Aug 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 4,400,000 $11.38 25,306,689 (indirect) +21% Aug 14, 2026
Derivative purchase Warrants (right to buy) 2,928,686 $11.38 — — Aug 14, 2026
James Woodruff Lillie Chief Scientific Officer · filed Aug 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 22,082 $12.54 202,380 −9.8% Aug 3, 2026
Catalyst4, Inc. 10% owner · filed Jul 30, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 1,000,000 $13.00 20,906,689 (indirect) +5.0% Jul 30, 2026
Open-market purchase 10b5-1 box not checked 3,000 $12.63 19,906,689 (indirect) +0.0% Jul 29, 2026
Open-market purchase 10b5-1 box not checked 141,088 $10.74 19,838,552 (indirect) +0.7% Jul 28, 2026
Open-market purchase 10b5-1 box not checked 65,137 $11.69 19,903,689 (indirect) +0.3% Jul 28, 2026
Troy Cox Director · filed Jul 28, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 15,620 $9.52 15,620 (indirect) — Jul 28, 2026
Anatol Kreitzer Chief Discovery Officer · filed Jul 20, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 200 $38.39 174,906 −0.1% Jul 17, 2026
Open-market sale 10b5-1 box checked 2,833 $37.05 189,246 −1.5% Jul 17, 2026
Open-market sale 10b5-1 box checked 14,140 $37.70 175,106 −7.5% Jul 17, 2026
Open-market sale 10b5-1 box checked 7,464 $36.66 193,671 −3.7% Jul 16, 2026
Open-market sale 10b5-1 box checked 1,592 $37.44 192,079 −0.8% Jul 16, 2026
Open-market sale 10b5-1 box checked 4,510 $36.94 201,135 −2.2% Jul 15, 2026
Open-market sale 10b5-1 box checked 5,545 $36.13 205,645 −2.6% Jul 15, 2026
Jonathan Gillis CAO and Interim CFO · filed Jul 20, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 16,969 $37.61 145,140 −10% Jul 17, 2026
Open-market sale 10b5-1 box checked 900 $38.17 144,240 −0.6% Jul 17, 2026
Open-market sale 10b5-1 box checked 600 $36.51 162,109 −0.4% Jul 17, 2026
Open-market sale 10b5-1 box checked 6,979 $36.66 164,185 −4.1% Jul 16, 2026
Open-market sale 10b5-1 box checked 1,476 $37.44 162,709 −0.9% Jul 16, 2026
Open-market sale 10b5-1 box checked 5,356 $36.13 175,863 −3.0% Jul 15, 2026
Open-market sale 10b5-1 box checked 4,699 $36.94 171,164 −2.7% Jul 15, 2026
Erin Pennock Foff Chief Medical Officer · filed Jul 17, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 3,656 $37.90 298,901 −1.2% Jul 17, 2026
Open-market sale 10b5-1 box checked 9,163 $36.46 308,441 −2.9% Jul 16, 2026
Open-market sale 10b5-1 box checked 5,865 $37.26 302,576 −1.9% Jul 16, 2026
Open-market sale 10b5-1 box checked 19 $37.96 302,557 −0.0% Jul 16, 2026
Open-market sale 10b5-1 box checked 7,155 $36.16 338,904 −2.1% Jul 15, 2026
Open-market sale 10b5-1 box checked 7,845 $37.04 331,059 −2.3% Jul 15, 2026
Open-market sale 10b5-1 box checked 4,465 $36.00 326,594 −1.3% Jul 15, 2026
Open-market sale 10b5-1 box checked 8,972 $36.99 317,622 −2.7% Jul 15, 2026
Open-market sale 10b5-1 box checked 18 $37.54 317,604 −0.0% Jul 15, 2026
Kristopher Hanson General Counsel · filed Jul 17, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 1,130 $37.90 145,823 −0.8% Jul 17, 2026
Open-market sale 10b5-1 box not checked 4,776 $36.45 150,295 −3.1% Jul 16, 2026
Open-market sale 10b5-1 box not checked 3,331 $37.26 146,964 −2.2% Jul 16, 2026
Open-market sale 10b5-1 box not checked 11 $37.96 146,953 −0.0% Jul 16, 2026
Open-market sale 10b5-1 box not checked 2,147 $36.00 160,184 −1.3% Jul 15, 2026
Open-market sale 10b5-1 box not checked 5,103 $36.99 155,081 −3.2% Jul 15, 2026
Open-market sale 10b5-1 box not checked 10 $37.54 155,071 −0.0% Jul 15, 2026
James Woodruff Lillie Chief Scientific Officer · filed Jul 17, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 2,077 $37.90 224,462 −0.9% Jul 17, 2026
Open-market sale 10b5-1 box not checked 5,009 $36.45 230,077 −2.1% Jul 16, 2026
Open-market sale 10b5-1 box not checked 3,526 $37.26 226,551 −1.5% Jul 16, 2026
Open-market sale 10b5-1 box not checked 12 $37.96 226,539 −0.0% Jul 16, 2026
Open-market sale 10b5-1 box not checked 5,393 $36.99 235,098 −2.2% Jul 15, 2026
Open-market sale 10b5-1 box not checked 12 $37.54 235,086 −0.0% Jul 15, 2026
Open-market sale 10b5-1 box not checked 2,238 $36.00 240,491 −0.9% Jul 15, 2026
Christopher A. Kroeger Chief Executive Officer · filed Jul 17, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 16,779 $37.90 1,246,455 −1.3% Jul 17, 2026
Open-market sale 10b5-1 box not checked 40,899 $36.46 1,291,417 −3.1% Jul 16, 2026
Open-market sale 10b5-1 box not checked 28,091 $37.26 1,263,326 −2.2% Jul 16, 2026
Open-market sale 10b5-1 box not checked 92 $37.96 1,263,234 −0.0% Jul 16, 2026
Open-market sale 10b5-1 box not checked 18,950 $36.00 1,375,144 −1.4% Jul 15, 2026
Open-market sale 10b5-1 box not checked 42,738 $36.99 1,332,406 −3.1% Jul 15, 2026
Open-market sale 10b5-1 box not checked 90 $37.54 1,332,316 −0.0% Jul 15, 2026
Nanna Liebach Luneborg Director · filed Jun 25, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 3,932 — 3,932 — Jun 23, 2026
Grant / award Stock Option (right to buy) 14,902 — — — Jun 23, 2026
Timothy John Garnett Director · filed Jun 25, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 3,932 — 53,457 +7.9% Jun 23, 2026
Grant / award Stock Option (right to buy) 14,902 — — — Jun 23, 2026

Listing the 25 most recent of 39 Form 4 filings held for MPLT; the 14 older filings (filed May 6 – Jun 25, 2026) are counted above but not listed here — see MPLT's full Form 4 filing history on SEC EDGAR.

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to MPLT's (Oct 16, 2026).

Frequently asked about MPLT insider activity

How many insiders bought MPLT stock in these Form 4 filings?

2 distinct insiders at MapLight Therapeutics, Inc. reported 6 open-market purchases (Form 4 code P) of MPLT shares between May 6, 2026 and Oct 16, 2026, the most recent filed by Catalyst4, Inc. (10% owner) on Aug 14, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Who filed the most recent Form 4 for MPLT?

The most recent Form 4 on this page was filed by Christopher A. Kroeger (Chief Executive Officer) on Oct 16, 2026, reporting 1 transaction. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market MPLT insider purchase shown?

The largest open-market purchase among the filings shown was 4,400,000 MPLT shares at $11.38 (about $50,072,000) by Catalyst4, Inc. (10% owner) on Aug 14, 2026. Value is shares × the price reported on the Form 4; its Rule 10b5-1 box is not checked.

Do the recent MPLT insider purchases have the Form 4 10b5-1 box checked?

No. All 6 MPLT open-market purchases shown were reported with the Rule 10b5-1 box not checked. A blank box records what the filer disclosed; it does not prove that no plan exists. Latest: Catalyst4, Inc. (10% owner) on Aug 14, 2026, 4,400,000 shares.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for MPLT — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.